📰 Hershel Berry News
Hershel Berry News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hershel Berry. Real-time updates on events, politics, business and more.
April 25, 2024
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed including...
April 25, 2024
Issuer: Mainz BioMed N.V. / Key word(s): Study results25.04.2024 / 15:29 CET/CESTThe issuer is solely responsible for the content of this announcement.Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Cli...
April 25, 2024
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed including previously unexamined and reported patients
April 9, 2024
Issuer: Mainz BioMed N.V. / Key word: Annual Results Mainz Biomed Reports Full Year 2023 Financial Results 09.04.2024 / 14:01 CET/CEST The issuer is solely responsible...
April 9, 2024
Issuer: Mainz Biomed N.V. / Key word(s): Annual Results Mainz Biomed Reports Full Year 2023 Financial Results 09.04.2...
March 12, 2024
Issuer: Mainz Biomed N.V. / Key word(s): Miscellaneous Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading t...
February 27, 2024
BERKELEY, Calif. and MAINZ, Germany, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its participation as an exhibitor at the esteemed Gynecology Congress (‘Gynäkologie und Geburtshilfe aktuell’) in Stuttgart, Germany, on March 1st. This engagement signifies the company's commitment to advanci...
February 21, 2024
Issuer: Mainz BioMed N.V. / Key word: Miscellaneous Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy 21.02.2024...
February 16, 2024
Detailed price information for Mainz Biomed N.V. (MYNZ-Q) from The Globe and Mail including charting and trades.
February 6, 2024
Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous06.02.2024 / 14:01 CET/CESTThe issuer is solely responsible for the content of this announcement.MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY Company opens own physician-led laboratory...